Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Arcus Biosciences (RCUS)

Arcus Biosciences Q3 revenue falls to $26 million; net loss widens to $135 million

Negative Impact 3 of 5 earnings Written later

Arcus Biosciences reported third-quarter 2025 revenue of $26 million, down from $48 million a year earlier, and a net loss of $135 million, up from $92 million. Research and development spending rose to $141 million as late-stage trials expanded, and cash, cash equivalents and marketable securities were $841 million at September 30, 2025, down from $992 million at December 31, 2024. The company expects full-year 2025 GAAP revenue of $225 million to $235 million, and it said it has paused recruitment in the Phase 1b portion of the eVOLVE-RCC02 study.

Key points

  • Q3 2025 revenue was $26 million, compared with $48 million in Q3 2024, mainly due to a $15 million license payment in the prior year
  • Q3 2025 net loss was $135 million, compared with $92 million in Q3 2024
  • Cash, cash equivalents and marketable securities were $841 million at September 30, 2025, versus $992 million at December 31, 2024
  • Full-year 2025 GAAP revenue is expected to be between $225 million and $235 million

The filing

CompanyArcus Biosciences (RCUS)
Form8-K, current report
Filed with the SECOct 28, 2025, 4:08 PM ET
Accession number0001724521-25-000114

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:49 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 28, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.